MAIA Biotech Private Fundraising of About $669,500 Announced
CHICAGO - MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical firm focused on targeted immunotherapies for cancer, has announced it has entered into definitive agreements for the sale of 446,332 shares of common stock at a price of $1.50 per share. This private placement to accredited investors and a company director is expected to raise around $669,500 in gross proceeds.
Each share of common stock comes with a warrant to purchase one share at an exercise price of $1.71 per share, with a term of five years. The warrants will be exercisable six months following the issuance. The securities being sold to the company director participating in the offering are being issued under the 2021 Equity Incentive Plan. The private placement is subject to customary closing conditions and is slated to close on or about May 29, 2025.
The net proceeds from the offering will be allocated to fund the execution of Step 1 of Part C of the Phase II trial THIO -101 and for working capital. The trial explores the combination of MAIA's lead drug candidate, THIO (ateganosine), with cemiplimab (Libtayo®) in non-small cell lung cancer (NSCLC) patients.
It is important to note that the securities being offered and sold, as well as the shares of common stock underlying the warrants, have not been registered under the Securities Act of 1933 or applicable state securities laws. These securities may not be offered or sold in the United States without registration or an applicable exemption.
About MAIA Biotechnology, Inc.:MAIA is a targeted therapy, immuno-oncology company developing potential first-in-class drugs with novel mechanisms of action. Their lead program, ateganosine (THIO), is a cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward-looking statements in this release are subject to known and unknown risks, uncertainties, and other factors that may cause the actual results, levels of activity, performance, or achievements of MAIA Biotechnology, Inc. to be materially different from those expressed or implied in these forward-looking statements.
For more details about investor relations, contact MAIA Biotechnology, Inc. at (872) 270-3518 or [email protected].
Sources:1. Business Wire (2025). MAIA Biotechnology Announces Private Placement of Common Stock and Warrants. [Link]2. MarketWatch (2025). MAIA Biotechnology Raises Additional Funds for Clinical Trials. [Link]3. GlobeNewswire (2025). MAIA Biotechnology's Private Placement Update. [Link]
- The private placement of common stock by MAIA Biotechnology, Inc. is expected to raise approximately $669,500, with the funds allocated towards the execution of a Phase II trial and working capital.
- The securities offered in this private placement will not be registered under the Securities Act of 1933 or applicable state securities laws, and therefore, cannot be sold in the United States without registration or an applicable exemption.
- MAIA Biotechnology, Inc., a company focused on targeted immunotherapies for cancer, recently made business news by announcing a private placement of common stock, with details available on various financial news platforms.
